Kala Pharmaceuticals (KALA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	49.20 mm	49.20 mm	49.20 mm	49.20 mm	49.20 mm	49.20 mm
Cash burn (monthly)	1.67 mm	571.75 k	3.33 mm	3.43 mm	1.58 mm	2.71 mm
Cash used (since last report)	7.11 mm	2.44 mm	14.22 mm	14.64 mm	6.73 mm	11.56 mm
Cash remaining	42.09 mm	46.76 mm	34.99 mm	34.56 mm	42.48 mm	37.64 mm
Runway (months of cash)	25.3	81.8	10.5	10.1	27.0	13.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

KALA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	22	17	+29.4%
Opened positions	10	3	+233.3%
Closed positions	5	20	-75.0%
Increased positions	1	2	-50.0%
Reduced positions	1	0	NEW

13F shares	Current	Prev Q	Change
Total value	5.20 bn	181.52 mm	+2763.9%
Total shares	17.57 mm	17.61 mm	-0.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Blumenkranz Mark S.	5.14 mm	$10.80 mm	0.0%
Lagunita	5.14 mm	$10.80 mm	0.0%
Lagunita Biosciences	5.14 mm	$10.80 mm	0.0%
Polaris Venture Partners V	598.62 k	$2.21 mm	0.0%
SR One Capital Management	445.64 k	$3.16 mm	0.0%
SR One Capital Management	443.66 k	$2.53 bn	NEW
ADAR1 Capital Management	306.07 k	$1.74 bn	NEW
Integrated Core Strategies	132.67 k	$0.00	0.0%
Longitude Capital Partners II	57.54 k	$884.00 k	0.0%
Vanguard	53.57 k	$305.35 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Baker Bros. Advisors	0.00	-891.34 k	EXIT
SR One Capital Management	443.66 k	+443.66 k	NEW
ADAR1 Capital Management	306.07 k	+306.07 k	NEW
Vanguard	53.57 k	+53.57 k	NEW
Virtu Financial	0.00	-31.10 k	EXIT
Renaissance Technologies	21.47 k	+21.47 k	NEW
BlackRock	21.36 k	+21.36 k	NEW
Board of Trustees of The Leland Stanford Junior University	21.13 k	+21.13 k	NEW
Geode Capital Management	37.12 k	+18.23 k	+96.5%
Banque Cantonale Vaudoise	0.00	-808.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KALA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Jan 25	Mark T Iwicki	Common Stock	Sell	Dispose S	No	Yes	7.63	5,779	44.09 k	280,076
6 Jan 25	Mark T Iwicki	Common Stock	Grant	Acquire A	No	No	0	22,100	0.00	285,855
6 Jan 25	Mark T Iwicki	Stock Option Common Stock	Grant	Acquire A	No	No	7.53	99,500	749.24 k	99,500
6 Jan 25	Reumuth Mary	Common Stock	Sell	Dispose S	No	Yes	7.63	1,706	13.02 k	68,581
6 Jan 25	Reumuth Mary	Common Stock	Grant	Acquire A	No	No	0	10,100	0.00	70,287
6 Jan 25	Reumuth Mary	Stock Option Common Stock	Grant	Acquire A	No	No	7.53	45,200	340.36 k	45,200
6 Jan 25	Brazzell Romulus K	Common Stock	Sell	Dispose S	No	Yes	7.63	2,446	18.66 k	92,418
6 Jan 25	Brazzell Romulus K	Common Stock	Grant	Acquire A	No	No	0	10,100	0.00	94,864
6 Jan 25	Brazzell Romulus K	Stock Option Common Stock	Grant	Acquire A	No	No	7.53	45,200	340.36 k	45,200
6 Jan 25	Darius Kharabi	Common Stock	Sell	Dispose S	No	Yes	7.63	2,021	15.42 k	67,807

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

15 Nov 24

HC Wainwright & Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:KALA) with a Buy and maintains $15 price target.

Press releases

From Benzinga Pro

KALA BIO Announces $10,750,000 Private Placement

30 Dec 24

ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 24

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for the CHASE trial in